Cargando…
Willingness to pay for an mHealth anti-retroviral therapy adherence and information tool: Transitioning to sustainability, Call for life randomised study experience in Uganda
INTRODUCTION: Evidence shows benefit of digital technology for people living with human immunodeficiency virus on antiretroviral therapy adherence and retention in care, however, scalability and sustainability have scarcely been evaluated. We assessed participants’ willingness to pay a fee for mHeal...
Autores principales: | Naggirinya, Agnes Bwanika, Kyomugisha, Eunice L., Nabaggala, Maria S., Nasasira, Benson, Akirana, Josephine, Oseku, Elizabeth, Kiragga, Agnes, Castelnuovo, Barbara, King, Rachel L., Katabira, Elly, Byonanebye, Dathan M., Lamorde, Mohammed, Parkes-Ratanshi, Rosalind |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8882291/ https://www.ncbi.nlm.nih.gov/pubmed/35219309 http://dx.doi.org/10.1186/s12911-022-01782-0 |
Ejemplares similares
-
An Interactive Voice Response Software to Improve the Quality of Life of People Living With HIV in Uganda: Randomized Controlled Trial
por: Byonanebye, Dathan Mirembe, et al.
Publicado: (2021) -
Acceptability of a Mobile Phone Support Tool (Call for Life Uganda) for Promoting Adherence to Antiretroviral Therapy Among Young Adults in a Randomized Controlled Trial: Exploratory Qualitative Study
por: Twimukye, Adelline, et al.
Publicado: (2021) -
Perceptions and Attitudes Toward an Interactive Voice Response Tool (Call for Life Uganda) Providing Adherence Support and Health Information to HIV-Positive Ugandans: Qualitative Study
por: Kajubi, Phoebe, et al.
Publicado: (2022) -
Impact of a mobile phone-based interactive voice response software on tuberculosis treatment outcomes in Uganda (CFL-TB): a protocol for a randomized controlled trial
por: Byonanebye, Dathan Mirembe, et al.
Publicado: (2021) -
An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir
por: Laker, Eva Agnes Odongpiny, et al.
Publicado: (2019)